Archives
-
Imatinib Hydrochloride: Mechanism & Research Workflow
2026-09-17
Imatinib hydrochloride, also known as STI571 hydrochloride, is a multi-target tyrosine kinase inhibitor for cancer research. Its documented activity against v-Abl, c-Kit, and PDGFR supports chronic myelogenous leukemia research, gastrointestinal stromal tumor research, and pathway-focused assay development.
-
RSL3 Glutathione Peroxidase 4 Inhibitor Guide
2026-09-17
RSL3 directly disables GPX4 to expose ferroptotic vulnerabilities in cancer, aging, and oxidative-stress models. This practical guide connects formulation, assay controls, lipid peroxidation readouts, and RAS-focused applications while separating literature-backed findings from optimization starting points.
-
Deferasirox Fe3+ Chelate Research Workflows
2026-09-16
Build reproducible iron-binding, ferric-complex, and cell-based assays with a defined DMSO-soluble reagent. This guide distinguishes preformed Deferasirox Fe3+ chelate from free deferasirox while translating clinical pharmacology into practical iron overload research workflows.
-
Ertapenem Sodium Salt in Resistance Research
2026-09-16
Ertapenem sodium salt enables controlled susceptibility testing and phenotype–genotype correlation in carbapenem-resistance studies. This workflow connects MIC profiling with plasmid localization, transmission analysis, and practical troubleshooting for CREC research.
-
Ferrostatin-1: Ferroptosis Assay Workflow
2026-09-15
Build a cleaner ferroptosis assay with Fer-1 rescue controls, lipid-ROS readouts, and a practical optimization plan. The workflow connects environmental toxicology findings with applications in cancer biology research, neuronal protection, and oxidative injury models.
-
Dye Models for Small Biopsy Handling
2026-09-15
The 2023 study by Nonsiri and colleagues evaluates whether selected dyes can improve the visibility of very small tissue biopsies during routine pathological preparation. Its main practical finding is that hematoxylin, rather than crystal violet, merbromin, or alcian blue, offers the most suitable balance of visibility, lower toxicity, and minimal interference with diagnostic slide examination.
-
Taihangia rupestris: Wild vs Cultivated Leaves
2026-09-14
A 2026 RSC Advances study combines UPLC-MS/MS, complementary antioxidant assays, α-glucosidase inhibition, affinity screening, and molecular docking to compare wild and cultivated Taihangia rupestris leaves. Foothill cultivation produced the strongest chemical and functional profiles, suggesting a conservation-compatible route for natural product antioxidant evaluation and antidiabetic research.
-
Aclacinomycin A in DNA Damage Workflows
2026-09-14
Aclacinomycin A, also called Aclarubicin, connects topoisomerase-driven DNA damage with caspase signaling, nucleolar stress, and proteasome assays. This practical guide shows how to build time-resolved workflows that distinguish persistent rDNA lesions from secondary cell death.
-
Tamoxifen Reprograms TAMs to Enhance Radiotherapy
2026-09-13
A 2026 Cancer Letters study identifies an immune mechanism by which high-dose Tamoxifen improves radiation responses: activation of the JNK/c-JUN pathway promotes M1-like polarization of tumor-associated macrophages (TAMs), which then supports CD8 T-cell activity. The findings provide preclinical rationale for combining Tamoxifen with radiotherapy in both estrogen receptor-positive and estrogen receptor-negative tumor models, while leaving clinical dose selection and safety unresolved.
-
Epacadostat: From IDO1 Kinetics to Immune Context
2026-09-12
Epacadostat (INCB024360) is an oral IDO1 inhibitor whose value depends on connecting enzyme inhibition with cellular and immune-context readouts. This guide presents an evidence-aware framework for choosing assays, interpreting kynurenine-pathway data, and evaluating checkpoint combinations.
-
Reserpine (N1867): Practical Lab Guide
2026-09-11
Reserpine (SKU N1867) provides a defined research reagent for controlled neurotransmitter depletion research and related neuropharmacology workflows, with documented purity, molecular weight, DMSO solubility, and storage requirements. It should be used only in appropriately controlled laboratory studies—not for diagnosis, treatment, or other medical applications.
-
Thapsigargin: From Ca2+ Trigger to Causal Assay
2026-09-11
Thapsigargin is a powerful SERCA pump inhibitor for tracing the sequence from calcium mobilization to ER stress, apoptosis, and inflammatory signaling. This guide translates respiratory disease evidence into a time-resolved assay strategy that separates mechanism from correlation.
-
YC-1 at the Hypoxia–Neuroinflammation Interface
2026-09-10
YC-1 is more than a conventional HIF-1α inhibitor: its concurrent activity as a soluble guanylyl cyclase activator creates a useful mechanistic probe for hypoxia, vascular biology, and tumor progression. This article connects that established oncology rationale with the Ca2+-dependent neuroinflammatory circuitry described in trigeminal neuralgia research, while clearly separating evidence from hypothesis.
-
Erastin for Ferroptosis Research Workflows
2026-09-10
Erastin provides a practical route for testing redox collapse and ferroptotic vulnerability in RAS- or BRAF-altered tumor models. This workflow combines genotype-aware experimental design, lipid-ROS measurements, viability testing, and mechanistic controls to distinguish ferroptosis from other forms of cell death.
-
Temafloxacin Workflows for Bacterial Research
2026-09-09
Temafloxacin supports comparative susceptibility testing, respiratory infection models, and intracellular mycobacterial workflows through a single fluoroquinolone scaffold. This guide translates reference-study findings into practical assay setup, optimization, troubleshooting, and evidence-aware experimental choices.